Mga Batayang Estadistika
| LEI | 549300UJLWOIWFDGB318 |
| CIK | 1070081 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PTC Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 19, 2025 |
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA Exhibit 99.1 PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA WARREN, N.J., August 19, 2025 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. “We a |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| August 7, 2025 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results – European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., August 7, 2025 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for t |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| July 28, 2025 |
EX-99.1 2 tmb-20250728xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) - Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older – - PTC will host a conference call on Monday, July 28th at 5:00 pm ET - WARREN, N.J., July 28, 2025 - PTC The |
|
| June 17, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| May 6, 2025 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results – Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio |
|
| May 5, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio |
|
| May 5, 2025 |
Exhibit 99.1 PTC518 PIVOT-HD Study Achieves Primary Endpoint - Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month |
|
| May 5, 2025 |
Exhibit 99.2 PTC Therapeutics PIVOT-HD Phase 2 Readout 1 Matthew B. Klein, MD CEO May 2025 PIVOT-HD Topline Results PTC Therapeutics PIVOT-HD Phase 2 Readout Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fa |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 28, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| March 28, 2025 |
Exhibit 99.2 EN EN EUROPEAN COMMISSION Brussels, 28.3.2025 C(2025) 2025 final COMMISSION IMPLEMENTING DECISION of 28.3.2025 refusing the renewal of the conditional marketing authorisation for the medicinal product for human use "Translarna - ataluren", granted by Decision C(2014)5619 final (Text with EEA relevance) (ONLY THE ENGLISH TEXT IS AUTHENTIC) EN 1 EN COMMISSION IMPLEMENTING DECISION of 28 |
|
| March 28, 2025 |
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe Exhibit 99.1 PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe WARREN, N.J., Mar. 28, 2025 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to not renew the authorization of Translarna™ (ataluren) for the |
|
| February 27, 2025 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results – Full year 2024 revenue of $807 million, exceeding guidance – – All 2024 clinical and regulatory milestones were achieved on schedule, including four NDA submissions, all of which were accepted for filing – – License and collaboration agreement with Novartis for PTC518 Huntingto |
|
| February 27, 2025 |
Exhibit 10.46 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. [**] denotes omissions. ASSET PURCHASE AGREEMENT BY AND BETWEEN [**] AND PTC THERAPEUTICS, INC. November 26, 2024 TABLE OF CONTENTS RECITALS1 ARTICLE 1 DEFINITIONS1 ARTICLE 2 PURCHASE AND SAL |
|
| February 27, 2025 |
Exhibit 10.47 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. [***] denotes omissions. LICENSE AND COLLABORATION AGREEMENT between PTC THERAPEUTICS, INC. PTC THERAPEUTICS HD, INC. and NOVARTIS PHARMACEUTICALS CORPORATION Dated as of November 27, 2024 TABL |
|
| February 27, 2025 |
Insider Trading Policy of the Registrant** Exhibit 19.1 INSIDER TRADING POLICY 1.0PURPOSE 1.1. The purpose of this Insider Trading Policy (“Policy”) is to help ensure that Federal and state securities laws, which prohibit the purchasing or selling of securities on the basis of material nonpublic information and from tipping material nonpublic information to others, is properly followed and abided by. Severe sanctions can be imposed on indi |
|
| February 27, 2025 |
Exhibit 10.36 Page 1 of 3 Page 2 of 3 |
|
| February 27, 2025 |
Subsidiaries of the Registrant** Exhibit 21.1 Significant Subsidiaries of PTC Therapeutics, Inc. Entity Name Jurisdiction of Incorporation PTC Therapeutics International Limited Ireland PTC Therapeutics GT, LLC Delaware PTC Therapeutics HD, Inc. Delaware PTC Therapeutics MP, Inc. Delaware PTC Therapeutics US, Inc. Delaware |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exact |
|
| February 27, 2025 |
Exhibit 10.34 [Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions] First AMENDMENT TO LEASE Agreement THIS FIRST AMENDMENT TO LEASE AGREEMENT (the “Amendment”) made as of December 31, 2024 (“Effective Date”), by and between |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| February 14, 2025 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2025 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of PTC Therapeutics, Inc. |
|
| January 13, 2025 |
Exhibit 99.2 1 PTC Therapeutics – JP Morgan 2025 Matthew B. Klein, MD CEO PTC Therapeutics 2025 Pam and Kelsey living with PKU PTC Therapeutics – JP Morgan 2025 3 PTC Therapeutics – JP Morgan 2025 PTC Therapeutics – JP Morgan 2025 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presen |
|
| January 13, 2025 |
Exhibit 99.1 PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference – Unaudited 2024 total revenue of approximately $814 million, exceeding guidance – – Four approval applications submitted to FDA in 2024 – – Global launch preparations underway for sepiapterin for PKU, a $1 billion market opportunity; CHMP opinion expected Q2 20 |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| January 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| December 2, 2024 |
Exhibit 99.1 PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program - PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global de |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| November 27, 2024 |
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million Exhibit 99.1 PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million WARREN, N.J., Nov. 27, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. PTC was granted the PRV on November 13, 2024 along with the U.S. F |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| November 14, 2024 |
PTCT / PTC Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ptct093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PTC THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 69366J200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* PTC Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of PTC Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 7, 2024 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results – Strong revenue performance, supporting increase in full-year revenue guidance to $750-800 million – – Regulatory filings for sepiapterin, Translarna™ and AADC gene therapy under review by FDA – – On track to achieve remaining 2024 clinical and regulatory milestones, including NDA submission f |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| October 18, 2024 |
Exhibit 99.1 CHMP Maintains Negative Opinion on Translarna™ Reexamination - Opinion to be reviewed by European Commission - WARREN, N.J., Oct. 18, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of |
|
| October 18, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| October 18, 2024 |
PTCT / PTC Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 PTCTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PTC THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 69366J200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| August 27, 2024 |
CLPT / ClearPoint Neuro, Inc. / Ptc Therapeutics, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2422646d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therap |
|
| August 8, 2024 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 1 TO AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT AND FIRST PUT OPTION EXERCISE AGREEMENT This AMENDMENT NO. 1 to the AMENDED AND RESTATED ROY |
|
| August 8, 2024 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (this "Agreement") is made and ent |
|
| August 8, 2024 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results – Continued strong revenue performance – – NDAs for sepiapterin and Translarna™ submitted to FDA – – Positive interim data readout from PTC518 PIVOT-HD study – – On track to achieve remaining 2024 clinical and regulatory milestones – WARREN, N.J., August 8, 2024 – PTC Therapeutics, Inc., (NASD |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| June 28, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| June 28, 2024 |
Exhibit 99.1 CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review - PTC to submit a request for re-examination - WARREN, N.J., June 28, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nmDMD. This op |
|
| June 20, 2024 |
Exhibit 99.2 1 PIVOT-HD Data Update – Q2 2024 Matthew Klein, M.D. CEO June 2024 PIVOT-HD Interim Results PIVOT-HD Data Update – Q2 2024 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-lookin |
|
| June 20, 2024 |
Exhibit 99.1 Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington’s Disease Patients - FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20th at 8:00 am EDT - WARREN, N.J., June 20, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today shared interim results from the Phase 2 |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| May 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporati |
|
| May 20, 2024 |
Exhibit 99.1 PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation - European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J., May 20, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided n |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 25, 2024 |
Employment Agreement between PTC Therapeutics, Inc. and Lee Golden Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of May 4, 2020 (the “Effective Date”), by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”) and Lee Golden (“Executive”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows: 1.Employment. The Company agrees to employ Executi |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| April 25, 2024 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results – Strong revenue performance across product portfolio – – Submitted MAA for sepiapterin and BLA for Upstaza – – On target to achieve remaining 2024 clinical and regulatory milestones, including global submissions for sepiapterin – WARREN, N.J., April 25, 2024 – PTC Therapeutics, Inc., (NASDAQ: |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exact |
|
| February 29, 2024 |
PTC Therapeutics, Inc. Clawback Policy** EXHIBIT 97.1 1.0PURPOSE 1.1.This Clawback Policy (this “Policy”), adopted by PTC Therapeutics, Inc. (the “Company”), relates to the Company’s right to recover compensation previously paid to specified employees in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D- |
|
| February 29, 2024 |
Exhibit 10.48 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT BY AND AMONG PTC THERAPEUTICS, INC., ROYALTY PHARMA INVESTMENTS 2019 ICAV AND SOLELY FOR THE PURPOSES OF SECTI |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| February 29, 2024 |
Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results – 34% year-over-year growth in 2023 total revenue – – Global filings of sepiapterin remain on track with first submission of the EU MAA expected in March – – Potential NDA submission for vatiquinone for Friedreich ataxia expected in late 2024 – SOUTH PLAINFIELD, N.J., Feb. 29, 20 |
|
| February 14, 2024 |
PTCT / PTC Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
PTCT / PTC Therapeutics, Inc. / RTW INVESTMENTS, LP - PTC THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* PTC Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan |
|
| February 13, 2024 |
PTCT / PTC Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01754-ptctherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: PTC Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 69366J200 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desi |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* PTC Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 25, 2024 |
EXHIBIT 99.1 CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure SOUTH PLAINFIELD, N.J., Jan. 25, 2024 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion following the re-examin |
|
| January 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| January 8, 2024 |
Exhibit 99.1 PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference – Unaudited 2023 total revenue of $946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts plan |
|
| January 8, 2024 |
Exhibit 99.2 PTC Therapeutics – JP Morgan 2024 Matthew B. Klein, MD CEO PTC Therapeutics 2024 Patient Living with PKU PTC Therapeutics – JP Morgan 2024 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, |
|
| November 7, 2023 |
As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. |
|
| October 30, 2023 |
EX-1 2 CamberPTCT13G2023ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated October 30, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities a |
|
| October 30, 2023 |
PTCT / PTC Therapeutics Inc / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PTC Therapeutics, Inc. (Name of Issuer) Common Stock $0.001 par value per share (Title of Class of Securities) 69366J200 (CUSIP Number) October 19, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| October 26, 2023 |
EXHIBIT 99.1 PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results – Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction – – PTC provides regulatory updates for pipeline programs – SOUTH PLAINFIELD, N.J., |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 19, 2023 |
EXHIBIT 99.1 PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing proceeds will be used to retire Blackstone debt obligations and fund planned operations - SOUTH PLAINFIELD, N.J., October 19, 2023 – PTC Therapeutics, Inc. (N |
|
| October 19, 2023 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incor |
|
| September 28, 2023 |
EXHIBIT 99.1 PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce - Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J., Sept. 28, 2023 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process initiated in May 202 |
|
| September 22, 2023 |
Exhibit 10.1 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CREDIT AGREEMENT dated as of October 27, 2022 among PTC THERAPEUTICS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER FROM TIME TO TIM |
|
| September 22, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 15, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incor |
|
| September 15, 2023 |
EXHIBIT 99.1 CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization - Conference call to be held at 8:45 am EDT - SOUTH PLAINFIELD, N.J., Sept. 15, 2023 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional mark |
|
| August 3, 2023 |
EXHIBIT 99.1 PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results – Second-quarter 2023 total revenue of $214 million, representing 29% year-over-year growth – – Positive APHENITY and PIVOT-HD data readouts in the second quarter – – Numerous regulatory milestones planned for the second half of 2023 – SOUTH PLAINFIELD, N.J., August 3, 2023 – PTC Therapeutics, Inc. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2023 |
EXHIBIT 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Amendment No. 5 to License Agreement This Amendment No. 5 (the “5th Amendment”) dated April 28, 2023 amends the License Agreement dated February 8, 2016 (the “ |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| July 19, 2023 |
Exhibit 99.1 Patient Living with PKU July 19, 2023 PTC Therapeutics PKU Deep Dive This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with respect to (i) 2023 total revenue guidance |
|
| July 17, 2023 |
EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 13, 2023 (the “Effective Date”), by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”) and Pierre Gravier (as more fully specified in Schedule 1.1, “Executive”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agr |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| June 21, 2023 |
Exhibit 99.1 PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington’s Disease Patients - Dose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks - - Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes - - Conference call and webcast to be held June 21st at 8:00 am EDT - SOUTH PLAINFIELD, N.J., June 21, |
|
| June 21, 2023 |
Exhibit 99.2 Patient Living with HD Matthew Klein, M.D. CEO June 2023 PIVOT -HD Interim Data Update 2 PIVOT-HD Interim Data Update Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking state |
|
| June 15, 2023 |
MRIC / MRI Interventions Inc / Ptc Therapeutics, Inc. - SC 13D/A Activist Investment SC 13D/A 1 tm2318790d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therap |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporati |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 23, 2023 |
Exhibit 99.1 PTC Therapeutics Announces Strategic Pipeline Prioritization - Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX - SOUTH PLAINFIELD, N.J., May 23, 2023 - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a stra |
|
| May 23, 2023 |
Patient Living with FA Matthew B. Klein, MD CEO MOVE - FA Topline Results Exhibit 99.3 Patient Living with FA Matthew B. Klein, MD CEO MOVE - FA Topline Results Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation, other than statements of historic fact, are forward - looking statements, including statements with re |
|
| May 23, 2023 |
EX-99.2 3 tm2316598d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial - Conference call and webcast to be held at 5:00 pm EDT - SOUTH PLAINFIELD, N.J., May 23, 2023 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The st |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporati |
|
| May 17, 2023 |
Exhibit 99.2 Patient Living with PKU Matthew Klein, M.D. CEO May, 2023 APHENITY Topline Results Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements with |
|
| May 17, 2023 |
EXHIBIT 99.1 PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients - Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population (p<0.0001) - - Conference call and webcast to be held at 8:00 AM EDT - SOUTH PLAINFIELD, N.J., May 17, 2023 - PTC Therapeutics, Inc. (NASDAQ: PTCT) today |
|
| May 5, 2023 |
Calculation of Filing Fee Tables EX-FILING FEES 4 tm2314782d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) PTC Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maxim |
|
| May 5, 2023 |
As filed with the Securities and Exchange Commission on May 5, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 27, 2023 |
Exhibit 99.1 PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results – First-quarter 2023 total revenue of $220 million, representing 48% year-over-year growth - – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – SOUTH PLAINFIELD, N.J., April 27, 2023 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today a |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| April 27, 2023 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SPONSORED RESEARCH AGREEMENT THIS SPONSORED RESEARCH AGREEMENT (the “Agreement”) is entered into as of June 1, 2006 (the “Effective Date”), by and between SPIN |
|
| April 27, 2023 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. DATED 26th of May 2010 (1) THE WELLCOME TRUST LIMITED and (2) PTC THERAPEUTICS, INC. AGREEMENT FOR THE PROVISION OF FUNDING TO PTC THERAPEUTICS, INC. FOR RESEA |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpora |
|
| April 18, 2023 |
EX-10.1 2 tmb-20230418xex10d1.htm EX-10.1 EXHIBIT 10.1 Execution Version AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made as of April 18, 2023 (the “Effective Date”), by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”) and Matthew Klein (“Executive”). This Agreement amends and restates in its entirety the E |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2023 PTC THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 24, 2023 |
Consulting Agreement between PTC Therapeutics, Inc. and Stuart W. Peltz Exhibit 10.1 Execution Version CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is entered into as of March 23, 2023 by and between PTC Therapeutics, Inc., a Delaware corporation (the “Company”), and Stuart W. Peltz, an individual (“Executive”). WHEREAS, effective as of March 24, 2023 (the “Effective Date”), Executive is retiring from his employment with the Company (“Retirement”) |
|
| March 24, 2023 |
Exhibit 99.1 Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics - Chief Operating Officer Matthew Klein, M.D., M.S., F.A.C.S. to become Chief Executive Officer and join the Board of Directors – - Conference call to be held today, Fri., March 24th at 8:30 am ET - SOUTH PLAINFIELD, N.J., March 24, 2023 / PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart P |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exa |
|
| February 21, 2023 |
Exhibit 99.1 PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results – 2022 total revenue of $699 million, representing 30% year-over-year growth, or $740 million and 37% growth at CER* – – Guidance for full-year 2023 total revenue of $940 million to $1 billion reaffirmed – – Four important study readouts expected in first half of 2023, three of |
|
| February 21, 2023 |
Power of attorney (included on the signature page to this Form 10-K) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC THERAPEUTICS, INC. (Exact |
|
| February 21, 2023 |
Exhibit 21.1 Significant Subsidiaries of PTC Therapeutics, Inc. PTC Therapeutics International Limited PTC Therapeutics GT, Inc. |
|
| February 21, 2023 |
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| February 21, 2023 |
Exhibit 10.19 PTC Therapeutics, Inc. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2013 Long-Term Incentive Plan 1. Grant of Option. This agreement evidences the grant by PTC Therapeutics, Inc., a Delaware corporation (the “Company”), on [Grant Date] (the “Grant Date”) to [Participant Name], an employee, consultant or advisor of the Company (the “Participant”), of an optio |
|
| February 21, 2023 |
Exhibit 10.56 Execution Version STOCK PURCHASE AGREEMENT BY AND AMONG THE INVESTORS LISTED HEREIN AND PTC THERAPEUTICS, INC. DATED AS OF OCTOBER 27, 2022 TABLE OF CONTENTS Page 1. Definitions1 1.1 Defined Terms1 1.2 Additional Defined Terms5 2. Purchase and Sale of Common Stock6 2.1 Purchase and Sale6 2.2 Tax Treatment6 3. Closing; Deliveries6 3.1 Closing6 3.2 Deliveries6 4. Representatio |
|
| February 21, 2023 |
Exhibit 10.20 PTC Therapeutics, Inc. Nonstatutory Stock Option Agreement Granted Under Amended and Restated 2013 Long-Term Incentive Plan 1.Grant of Option. This Agreement evidences the grant by PTC Therapeutics, Inc., a Delaware corporation (the “Company”), on [Grant Date] (the “Grant Date”) to [Participant Name] a director of the Company (the “Participant”), of an option to purchase, in whole or |
|
| February 21, 2023 |
Exhibit 10.55 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CREDIT AGREEMENT dated as of October 27, 2022 among PTC THERAPEUTICS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER FROM TIME TO TI |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorp |
|
| February 21, 2023 |
Exhibit 10.21 PTC Therapeutics, Inc. Restricted Stock Unit Agreement PTC Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its Amended and Restated 2013 Long-Term Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): [Participant Name] Grant Date: [Grant Date] Number of |
|
| February 21, 2023 |
Exhibit 10.18 PTC Therapeutics, Inc. Incentive Stock Option Agreement Granted Under Amended and Restated 2013 Long-Term Incentive Plan 1. Grant of Option. This agreement evidences the grant by PTC Therapeutics, Inc., a Delaware corporation (the “Company”), on [Grant Date] (the “Grant Date”) to [Participant Name], an employee of the Company (the “Participant”), of an option to purchase, in whole or |
|
| February 14, 2023 |
PTCT / PTC Therapeutics, Inc. / RTW INVESTMENTS, LP - PTC THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0495sc13ga.htm PTC THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* PTC Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Ch |
|
| February 9, 2023 |
PTCT / PTC Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01726-ptctherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: PTC Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 69366J200 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to des |
|
| February 6, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* PTC Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 1, 2023 |
PTCT / PTC Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment ptct22a4.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 69366J200 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* PTC Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2022 (Date |
|
| January 9, 2023 |
EX-99.1 2 tmb-20230109xex99d1.htm EX-99.1 EXHIBIT 99.1 PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference - ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth – - $940 million - $1.0 billion 2023 total revenue guidance – - Results from three registration-directed clinical tr |
|
| January 9, 2023 |
EX-99.2 3 tmb-20230109xex99d2.htm EX-99.2 Exhibit 99.2 PKU Patient Matthew Klein, M.D., COO JP Morgan Healthcare Conference January 9, 2023 PTC 2023 Forward - qLooqking Statements This prqesqeqntatioqn coqntaiqns forward - lookiqng statqemqeqnts withiqn thqe mqeaqniqng of Thqe Privatqe Sqecuritiqes Litigatioqn Rqeform Act of 1995 . All statqemqeqnts coqntaiqnqed iqn this prqesqeqntatioqn, othqer t |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpor |
|
| December 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) PTC Therapeutics, Inc. |
|
| December 16, 2022 |
As filed with the Securities and Exchange Commission on December 16, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 16, 2022 Registration No. |
|
| December 16, 2022 |
As filed with the Securities and Exchange Commission on December 16, 2022 As filed with the Securities and Exchange Commission on December 16, 2022 Registration No. |
|
| December 16, 2022 |
Exhibit 99.4 AMENDMENT NO. 3 TO 2020 INDUCEMENT STOCK INCENTIVE PLAN OF PTC THERAPEUTICS, INC. The 2020 Inducement Stock Incentive Plan (the ?Plan?) of PTC Therapeutics, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and hereby is deleted i |
|
| December 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) PTC Therapeutics, Inc. |
|
| December 6, 2022 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF PTC THERAPEUTICS, INC. ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place, if any, as may be designated from time to time by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President or, if not so designated, at the principal executive office of the corporation. The |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 5, 2022 PTC THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Delaware 001-35969 04-3416587 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 6, 2022 |
Consulting Services Agreement between the Registrant and Dawn Svoronos Exhibit 10.1 PTC CONSULTING SERVICES AGREEMENT This Consulting Services Agreement, effective as December 6, 2022 (the ?Effective Date?) between PTC Therapeutics, Inc., a Delaware corporation (?PTC? or the ?Company?) and Dawn Svoronos (the ?Consultant?). WHEREAS, the Consultant has served as a member of the Board of Directors of PTC (the ?Board?), and in such capacity has participated in the oversi |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 PTC THERAPEUTICS, INC. (Exact name of registrant as specified in charter) Delaware 001-35969 04-3416587 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| October 27, 2022 |
Exhibit 99.1 PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding - Blackstone investment accelerates innovative product pipeline – - PTC will leverage Blackstone’s network and life sciences expertise to broaden business development effort – - PTC to receive $350 million in cash at close - SOUTH PLAINFIELD, N.J., & NEW YORK, N.Y. Oct. 27, 20 |
|
| October 27, 2022 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CONFIDENTIAL July 25, 2022 Adrian Haigh Director; Senior Vice President, Head of International, PTC Therapeutics International Limited 5th Floor 3 Grand Plaza |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 27, 2022 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CONFIDENTIAL September 14, 2022 Brett Monia President Akcea Therapeutics, Inc. Re: Collaboration and License Agreement dated August 1, 2018 (the “Agreement”) b |
|
| October 27, 2022 |
EXHIBIT 99.1 PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results - Total quarterly revenue of $217 million, representing 57% year-over-year growth – - 2022 DMD revenue guidance and low end of total revenue guidance increased - - Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital - - Pipeline of multiple innovative c |
|
| October 18, 2022 |
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 EXHIBIT 99.1 PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 SOUTH PLAINFIELD, N.J., Oct. 18, 2022 - PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the treatment of Huntington?s disease at study sites globally. To date, PTC has received approval for conduct of the planned 12-month study in sev |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| September 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 7, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? ( |
|
| September 7, 2022 |
Exhibit 99.1 PTC 2022 Corporate Presentation September 2022 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. All statements contained in this presentation, other than statements of historic fact, are forward - looking statements, including statements with respect to guidance relating t |
|
| August 15, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 15, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Co |
|
| August 4, 2022 |
Exhibit 10.1 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions ? LEASE AGREEMENT ? BETWEEN WARREN CC ACQUISITIONS, LLC, a Delaware limited liability company, ? LANDLORD, ? -AND- PTC THERAPEUTICS, INC., a Delaware Corporat |
|
| August 4, 2022 |
Exhibit 10.2 ? Page:1 / 6 ? ? ? DATE OF ISSUE: ? ? ? 22JUN2022 ? ? ? ? IRREVOCABLE TRANSFERABLE STANDBY DOC. CREDIT NO. SDCMTN582868 ? ? ? ? ? BENEFICIARY: APPLICANT: ? ? ? ? WARREN CC AQUISITIONS LLC PTC THERAPEUTICS INC ? ? ? ? C/O VISION REAL ESTATE PARTNERS. 100 CORPORATE CT ? ? ? ? LLC,1 BLOOMFIELD AVENUE SOUTH PLAINFIELD. NJ 07080 ? ? ? ? MOUNTAIN LAKES. NEW JERSEY 07046 ? ? ? ? ? ? ? ? ? ? |
|
| August 4, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 4, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Com |
|
| August 4, 2022 |
EX-99.1 2 tmb-20220804xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results - Total revenue of $166 million, representing 42% year-over-year growth – - Upstaza™ gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated – SOUTH PLAINFIELD, N.J., Augus |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 11, 2022 |
PTCT / PTC Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: PTC Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 69366J200 Date of Event Which Requires Filing of this Statement: June 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R |
|
| June 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables ? Form S-8 (Form Type) PTC Therapeutics, Inc. |
|
| June 23, 2022 |
As filed with the Securities and Exchange Commission on June 23, 2022 As filed with the Securities and Exchange Commission on June 23, 2022 Registration No. |
|
| June 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 21, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Comm |
|
| June 21, 2022 |
Exhibit 99.1 Translarna?(Ataluren)Study 041 Topline Results21stJune 2022 Forward looking statementsThis presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectati |
|
| June 9, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 8, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Commi |
|
| June 9, 2022 |
EX-10.1 2 tmb-20220608xex10d1.htm PTC THERAPEUTICS, INC. AMENDED AND RESTATED 2013 LONG-TERM INCENTIVE PLAN EXHIBIT 10.1 PTC Therapeutics, Inc. Amended and Restated 2013 Long-Term Incentive Plan 1.Purpose The purpose of this Amended and Restated 2013 Long-Term Incentive Plan (the “Plan”) of PTC Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s |
|
| June 9, 2022 |
Exhibit 99.1 PTC Therapeutics William Blair Growth Stock Conference Matthew Klein, M.D. Chief Operating Officer Kylie O?Keefe, SVP Global Commercial and Corporate Strategy June 9, 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .. All statements contained in this presentation, other t |
|
| May 27, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 24, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Commi |
|
| May 3, 2022 |
Exhibit 10.1 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? Collaborative Research Agreement Amendment No. 11 This Amendment No. 11 is made and entered into as of the last date of signature (the ?Amendment 11 Effect |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 3, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 3, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Commis |
|
| May 3, 2022 |
Exhibit 99.1 ? ? ? PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results ? - $149 million total revenue representing impressive 26% year-over-year growth ? - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington?s disease ? - CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch ? ? SOUTH PLAINFIELD, N.J., May 3, 2022 ? PT |
|
| May 3, 2022 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COMMERCIAL MANUFACTURING AGREEMENT THIS MANUFACTURING AGREEMENT (the ?Agreement?) is made and entered into this 18th day of September, 2015 (the ?Effective Dat |
|
| April 28, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 28, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 15, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 13, 2022 |
As filed with the Securities and Exchange Commission on April 13, 2022 As filed with the Securities and Exchange Commission on April 13, 2022 Registration No. |
|
| April 13, 2022 |
EXHIBIT 99.1 AMENDMENT NO. 2 TO 2020 INDUCEMENT STOCK INCENTIVE PLAN OF PTC THERAPEUTICS, INC. The 2020 Inducement Stock Incentive Plan (the ?Plan?) of PTC Therapeutics, Inc. (the ?Company?) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Section 4(a)(1) of the Plan be and hereby is deleted i |
|
| February 22, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 22, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? ( |
|
| February 22, 2022 |
EXHIBIT 99.1 ? ? ? PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results ? - $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline progress with five registration-directed clinical trials ongoing ? - $700-750 million 2022 total revenue guidance reaffirmed ? ? SOUTH PLAINFIELD, N.J., Feb 22, 20 |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 22, 2022 |
Exhibit 10.53 ? Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ? Collaborative Research Agreement Amendment No. 10 This Amendment No. 10 is made and entered into as of the last date of signature (the ?Amendment 10 Effective |
|
| February 22, 2022 |
Exhibit 10.44 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made as of October 28, 2019 (the ?Effective Date?), by and between PTC Therapeutics, Inc., a Delaware corporation (the ?Company?) and Matthew Klein (?Executive?). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows: 1.Employment. The Company agrees to emplo |
|
| February 22, 2022 |
Exhibit 4.1 ? DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT ? The following description of registered securities of PTC Therapeutics, Inc. is intended as a summary only and therefore is not a complete description. The description is based upon, and is qualified by reference to, our certificate of incorporation, as amended, our amended and restated bylaws and applicable |
|
| February 14, 2022 |
PTCT / PTC Therapeutics, Inc. / RTW INVESTMENTS, LP Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* PTC Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan |
|
| February 11, 2022 |
PTCT / PTC Therapeutics, Inc. / HARTFORD MUTUAL FUNDS INC/CT - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PTC Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) 12/31/2021 (Date of Event Which |
|
| February 10, 2022 |
PTCT / PTC Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: PTC Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 69366J200 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 7, 2022 |
PTCT / PTC Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment ptct21a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 69366J200 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* PTC Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2021 (Date |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* PTC Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 10, 2022 |
EXHIBIT 99.1 ? ? ? ? PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference - $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth - - $700 - 750 million 2022 total revenue guidance - - Results are expected in four registration-directed trials this year - - Three additional registration-dir |
|
| January 10, 2022 |
Exhibit 99.2 PTC 2022J.P. Morgan Healthcare Conference Stuart W. Peltz, Ph.D., CEO Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historic fact, are forward-looking statements,including statements with respect to prelim |
|
| January 10, 2022 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): January 7, 2022 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Co |
|
| January 5, 2022 |
As filed with the Securities and Exchange Commission on January 5, 2022 As filed with the Securities and Exchange Commission on January 5, 2022 Registration No. |
|
| November 30, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 30, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? ( |
|
| November 30, 2021 |
Exhibit 99.1 PTC 2021 Corporate Deck Updated Nov 30, 2021 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 199 5. All statements contained in this release, other than statements of historic fact, are forward -looking statements, including statements with respect to 2021 net product revenue guidanc |
|
| October 28, 2021 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 28, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (C |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 28, 2021 |
EXHIBIT 99.1 ? ? ? PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results ? - Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of P |
|
| October 19, 2021 |
October 19, 2021 Mr. Gary Newberry Ms. Mary Mast Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: PTC Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Response dated September 23, 2021 File No. 001-35969 Dear Mr. Newberry and Ms. Mast: This letter is submitted on behalf of PT |
|
| September 23, 2021 |
September 23, 2021 Mr. Gary Newberry Ms. Mary Mast Office of Life Sciences United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: PTC Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 25, 2021 File No. 001-35969 Dear Mr. Newberry and Ms. Mast: This letter is submitted on behalf of PTC Therap |
|
| September 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 23, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? |
|
| September 23, 2021 |
Exhibit 99.1 PTC518 Huntington?s Disease Program Update September 23, 2021 Forward Looking Statements: This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including statements regarding: the future expectati |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorporat |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 29, 2021 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF PTC THERAPEUTICS, INC. (originally incorporated on March 31, 1998) PTC Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A.The current name of the Corporation is PTC Therapeutics, Inc. The orig |
|
| July 29, 2021 |
EX-99.1 2 ptct-20210729ex991e55f61.htm EX-99.1 EXHIBIT 99.1 PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress across robust clinical pipeline with 3 ongoing registration-directed t |
|
| June 9, 2021 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 8, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Commi |
|
| June 9, 2021 |
Certificate of Amendment to the Restated Certificate of Incorporation of PTC Therapeutics, Inc. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION OF PTC THERAPEUTICS, INC. ? PTC Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: ? A.The current name of the Corporation is PTC Therapeutics, Inc. The original Cer |
|
| June 9, 2021 |
EX-10.1 3 ptct-20210608ex10141119a.htm EX-10.1 EXHIBIT 10.1 PTC THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN The purpose of this Amended and Restated 2016 Employee Stock Purchase Plan (this "Plan") is to provide eligible employees of PTC Therapeutics, Inc. (the "Company") and certain of its subsidiaries with opportunities to purchase shares of the Company's common stoc |
|
| May 4, 2021 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 4, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Commis |
|
| May 4, 2021 |
EX-99.1 2 ptct-20210504ex9919ca02a.htm EX-99.1 EXHIBIT 99.1 PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results - PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial - - Total net revenue of $118 million; 73% increase over first quarter 2020 - - DMD franchise net product revenue of $90 millio |
|
| May 4, 2021 |
Exhibit 10.1 ? Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. ? Collaborative Research Agreement Amendment No. 9 This Amendment No. 9 is made and entered into as of March 21, 2021 (the ?Amendment 9 Effective Date") to that certain |
|
| May 4, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? |
|
| April 16, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits ? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): April 15, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? (Com |
|
| April 15, 2021 |
Exhibit 99.1 PTC518 Huntington’s Disease Deep Dive April 15th, 2021 Forward Looking Statements: This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward -looking statements, including statements with respect to the future expectation |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 100 Corporate Court South Pla |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 26, 2021 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of PTC Therapeutics, Inc. |
|
| February 25, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2021 |
? ? UNITED STATES ? SECURITIES AND EXCHANGE COMMISSION ? WASHINGTON, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 25, 2021 ? PTC THERAPEUTICS, INC. ? (Exact Name of Company as Specified in Charter) ? ? ? ? ? ? Delaware 001-35969 04-3416587 (State or Other Jurisdiction ? ( |
|
| February 25, 2021 |
Exhibit 99.1 ? ? ? ? PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update - $333 million 2020 total net product revenue representing 14% year-over-year growth - - Advancing multiple registration-directed clinical trials - - PTC518 healthy volunteer data expected in the first half of 2021 for Huntington disease program - - 2021 DMD franchise r |
|
| February 25, 2021 |
Exhibit 10.50 ? Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. ? Collaborative Research Agreement Amendment No. 7 This Amendment No. 7 is made and entered into as of the last date signed below (the ?Amendment 7 Effective Date") to that certain Collaborative Res |
|
| February 25, 2021 |
EX-10.51 3 ptct-20201231ex10512e2d9.htm EX-10.51 Exhibit 10.51 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. Collaborative Research Agreement Amendment No. 8 This Amendment No. 8 is made and entered into as of December 5, 2020 (t |
|
| February 12, 2021 |
JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) EX-1 2 ex1.htm Exhibit 1 JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 1 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, of PTC Therapeutics, Inc., together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: PTC Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 69366J200 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* PTC Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) 12/31/2020 (Date of Event Which |
|
| February 4, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2021 PTC THERAPEUTICS, INC. (Exact Name of Company as Specified in Charter) Delaware 001-35969 04-3416587 (State or Other Jurisdiction (Commission (IRS Employer of Incorpo |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* PTC Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69366J200 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 4, 2021 |
EX-99.1 2 tmb-20210204xex99d1.htm EX-99.1 Exhibit 99.1 PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J., Feb. 4, 2021 - PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of Translarna™ (at |
|
| February 4, 2021 |
Exhibit 99.2 Translarna™ Study 045 and Clinical Update Stuart W. Peltz, Ph.D. Chief Executive Officer Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation, other than statements of historic fact, are forward -looking statements, including statements |
